FORMELA JEAN FRANCOIS 4

What Happened Formela Jean Francois, a director of Korro Bio, sold a total of 2,860 shares in open‑market transactions on May 28, 2026. The sales were in two lots: 2,441 shares at $13.95 each (proceeds $34,052) and 419 shares at $13.95 each (proceeds $5,845), for total gross proceeds of about $39,897. These transactions are reported as sales (code S).

Key Details

• Transaction date: 2026-05-28. Price per share: $13.95.
• Lots: 2,441 shares ($34,052) and 419 shares ($5,845); total 2,860 shares (~$39,897).
• Method: Open market or private sale, reported as sales (S).
• Plan/authorization: Filed footnote F1 — shares sold pursuant to a Rule 10b5-1 trading plan adopted April 8, 2026.
• Ownership notes: Footnotes F2 and F3 indicate certain shares are held by Atlas venture funds and the reporting person disclaims Section 16 beneficial ownership of those fund‑held shares except to the extent of any pecuniary interest.
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Timeliness: Reported on 2026-06-01 for a 2026-05-28 transaction; filing appears to be timely (not marked late).

Context Sales conducted under a Rule 10b5-1 plan are prearranged and are typically considered routine disposition plans rather than ad hoc sales; the filing simply reports those sales and does not indicate the director’s private views on the company. For retail investors, purchases tend to carry more informational weight than routine sales; this filing documents a modest insider sale of roughly $40k.